Roivant Sciences Ltd. (NASDAQ:ROIV) saw an upside of 0.83% to close Monday at $10.96 after adding $0.09 on the day. The 5-day average trading volume is 4,553,480 shares of the company’s common stock. It has gained $11.75 in the past week and touched a new high 1 time within the past 5 days. An average of 3,315,195 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 5,533,660.
ROIV’s 1-month performance is -1.17% or -$0.13 on its low of $10.24 reached on 08/18/23. The company’s shares have touched a 52-week low of $2.87 and high of $12.01, with the stock’s rally to the 52-week high happening on 07/18/23. YTD, ROIV has achieved 37.17% or $2.97 and has reached a new high 13 times. However, the current price is down -8.70% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ROIV stock investors last saw insider trading activity on Aug 14.Venker Eric (Chief Operating Officer) most recently sold 59,811 shares at $11.89 per share on Aug 14. This transaction cost the insider $711,153. Chief Operating Officer, Venker Eric, sold 44,629 shares at a price of $11.93 on Aug 03. Then, on Aug 03, Chief Accounting Officer Kumar Rakhi sold 3,681 shares at a price of $12.00 per share. This transaction amounted to $44,172.
Valuation Metrics
ROIV stock has a beta of 1.31. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 103.65 while the price-to-book (PB) in the most recent quarter is 9.13.
Roivant Sciences Ltd.’s quick ratio for the period ended June 29 was 6.40, with the current ratio over the same period at 6.40. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.42, while the total debt to equity was 0.47. In terms of profitability, the gross margin trailing 12 months is 80.10%. The firm’s gross profit as reported stood at $48.15 million against revenue of $61.28 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -13.7% to -$291.82 million, while revenue of -$33.62 million was 88.48% off the previous quarter. Analysts expected ROIV to announce -$0.3 per share in earnings in its latest quarter, but it posted -$0.38, representing a -26.70% surprise. EBITDA for the quarter stood at more than -$270.57 million. ROIV stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 802.51 million, with total debt at $492.64 million. Shareholders hold equity totaling $771.74 million.
Let’s look briefly at Roivant Sciences Ltd. (ROIV) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 21 August was 45.60% to suggest the stock is trending Neutral, with historical volatility in this time period at 46.24%.
The stock’s 5-day moving average is $10.82, reflecting a -6.40% or -$0.75 change from its current price. ROIV is currently trading +2.14% above its 20-day SMA, +49.12% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +14.41% and SMA200 by+106.79%.
Stochastic %K and %D was 28.54% and 20.77% and the average true range (ATR) pointed at 0.54. The RSI (14) points at 48.12%, while the 14-day stochastic is at 40.91% with the period’s ATR at 0.52. The stock’s 9-day MACD Oscillator is pointing at -0.35 and -0.49 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Roivant Sciences Ltd. (NASDAQ: ROIV), BofA Securities launched coverage with a Neutral rating. Analysts offering their rating for ROIV stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ROIV as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 8 have offered a “buy” rating.
What is ROIV’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $12.00 and a high of $23.00, with their median price target at $15.00. Looking at these predictions, the average price target given by analysts is for Roivant Sciences Ltd. (ROIV) stock is $15.88.
